Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry
Molecular & Cellular Proteomics · 2023-06 · 22 (6) · 100563
DOI: 10.1016/j.mcpro.2023.100563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2023-06. Verfasst von Kshiti Meera Phulphagar und 9 weiteren Autor:innen. Hauptthemen laut MEDLINE: Histocompatibility Antigens Class I, Neoplasms. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Swiss National Science Foundation, National Institutes of Health.
Abstract (Originalsprache)
Comprehensive and in-depth identification of the human leukocyte antigen class I (HLA-I) and class II (HLA-II) tumor immunopeptidome can inform the development of cancer immunotherapies. Mass spectrometry (MS) is a powerful technology for direct identification of HLA peptides from patient-derived tumor samples or cell lines. However, achieving sufficient coverage to detect rare and clinically relevant antigens requires highly sensitive MS-based acquisition methods and large amounts of sample. While immunopeptidome depth can be increased by off-line fractionation prior to MS, its use is impractical when analyzing limited amounts of primary tissue biopsies. To address this challenge, we developed and applied a high-throughput, sensitive, and single-shot MS-based immunopeptidomics workflow that leverages trapped ion mobility time-of-flight MS on the Bruker timsTOF single-cell proteomics system (SCP). We demonstrate greater than twofold improved coverage of HLA immunopeptidomes relative to prior methods with up to 15,000 distinct HLA-I and HLA-II peptides from 4e7 cells. Our optimized single-shot MS acquisition method on the timsTOF SCP maintains high coverage, eliminates the need for off-line fractionation, and reduces input requirements to as few as 1e6 A375 cells for >800 distinct HLA-I peptides. This depth is sufficient to identify HLA-I peptides derived from cancer-testis antigen and noncanonical proteins. We also apply our optimized single-shot SCP acquisition methods to tumor-derived samples, enabling sensitive, high-throughput, and reproducible immunopeptidome profiling with detection of clinically relevant peptides from less than 4e7 cells or 15 mg wet weight tissue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Förderung
- NCI NIH HHS
- Swiss National Science Foundation
- National Institutes of Health
- National Cancer Institute
- Broad Institute
- Doctor Miriam and Sheldon G Adelson Medical Research Foundation
Zitieren
APA
Phulphagar, K. M., Ctortecka, C., Jacome, A. S. V., Klaeger, S., Verzani, E. K., Hernandez, G. M., Udeshi, N. D., Clauser, K. R., Abelin, J. G., & Carr, S. A. (2023). Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry. Molecular & Cellular Proteomics, 22(6), 100563. https://doi.org/10.1016/j.mcpro.2023.100563
Vancouver
Phulphagar KM, Ctortecka C, Jacome ASV, Klaeger S, Verzani EK, Hernandez GM, et al. Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry. Molecular & Cellular Proteomics. 2023;22(6):100563. doi:10.1016/j.mcpro.2023.100563
BibTeX
@article{Phulphagar2023,
author = {Phulphagar, Kshiti Meera and Ctortecka, Claudia and Jacome, Alvaro Sebastian Vaca and Klaeger, Susan and Verzani, Eva K and Hernandez, Gabrielle M and Udeshi, Namrata D and Clauser, Karl R and Abelin, Jennifer G and Carr, Steven A},
title = {Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry},
journal = {Molecular & Cellular Proteomics},
year = {2023},
volume = {22},
number = {6},
pages = {100563},
doi = {10.1016/j.mcpro.2023.100563}
}
EUVIMED